Accretion Pharmaceuticals (ACCPL) Stock Overview
Engages in the manufacturing and marketing of pharmaceutical products in India. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
ACCPL Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Accretion Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹154.00 |
| 52 Week High | ₹171.15 |
| 52 Week Low | ₹53.80 |
| Beta | 0 |
| 1 Month Change | 6.28% |
| 3 Month Change | 90.12% |
| 1 Year Change | 130.02% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 85.65% |
Recent News & Updates
Recent updates
Shareholder Returns
| ACCPL | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -5.6% | 2.3% | 1.8% |
| 1Y | 130.0% | 13.2% | -0.9% |
Return vs Industry: ACCPL exceeded the Indian Pharmaceuticals industry which returned 13.2% over the past year.
Return vs Market: ACCPL exceeded the Indian Market which returned -0.9% over the past year.
Price Volatility
| ACCPL volatility | |
|---|---|
| ACCPL Average Weekly Movement | 7.9% |
| Pharmaceuticals Industry Average Movement | 6.5% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in IN Market | 9.3% |
| 10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: ACCPL's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: ACCPL's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 125 | Vivek Ashok Patel | www.accretionpharma.com |
Accretion Pharmaceuticals Limited engages in the manufacturing and marketing of pharmaceutical products in India. The company offers antibiotic, antibacterial, antifungal, anti-inflammatory, anti-spasmodic, antihistamine, antiallergy, anticough, anticold, antiulcer, gastrointestinal, antacid, anti-diabetic, cardiac, anti-hypertensive, psychotropic, memory enhancer, vitamins, supplements, and other products. It also provides external preparation, oral powder, effervescent formulation, and nutraceutical products, as well as formulations for brain and memory care, neuron care, UTI care, cardiac care, liver care, protein supplement, pediatric care, GIT care, joint and bone care, immunity booster, gynec care, hair and skin care, nail care, and infertility, and PCOS care.
Accretion Pharmaceuticals Limited Fundamentals Summary
| ACCPL fundamental statistics | |
|---|---|
| Market cap | ₹1.77b |
| Earnings (TTM) | ₹96.68m |
| Revenue (TTM) | ₹898.18m |
Is ACCPL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACCPL income statement (TTM) | |
|---|---|
| Revenue | ₹898.18m |
| Cost of Revenue | ₹651.53m |
| Gross Profit | ₹246.65m |
| Other Expenses | ₹149.97m |
| Earnings | ₹96.68m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 8.70 |
| Gross Margin | 27.46% |
| Net Profit Margin | 10.76% |
| Debt/Equity Ratio | 22.5% |
How did ACCPL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/07 15:27 |
| End of Day Share Price | 2026/07/07 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Accretion Pharmaceuticals Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.